Financhill
Back

Fulcrum Therapeutics Quote, Financials, Valuation and Earnings

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!
Sell
36

FULC
Fulcrum Therapeutics

Last Price:
3.27
Seasonality Move:
85.55%

7 Day Trial

ALL ACCESS PASS

$ 7

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!

Fulcrum Therapeutics Price Quote

$3.27
+0.01 (+1.87%)
(Updated: November 5, 2024 at 5:25 AM ET)

Fulcrum Therapeutics Key Stats

Sell
36
Fulcrum Therapeutics (FULC) is a Sell

Day range:
$3.13 - $3.38
52-week range:
$2.87 - $13.70
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.74%

Volume:
767.2K
Avg. volume:
971.6K
1-year change:
-16.2%
Market cap:
$203.4M
Revenue:
$2.8M
EPS:
$-0.35

How Much Does Fulcrum Therapeutics Make?

Data Unavailable

Is Fulcrum Therapeutics Growing As A Company?

  • What Is Fulcrum Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 89.91%
  • What Is Fulcrum Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Fulcrum Therapeutics Stock Price Performance

What Is Fulcrum Therapeutics 52-Week High & Low?

Fulcrum Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Fulcrum Therapeutics?

Is Fulcrum Therapeutics Cash Flow Positive?

  • What Is FULC Cash Flow From Operations?
    Cash flow from operations (TTM) is -$12.4M
  • What Is Fulcrum Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $2.3M
  • What Is Fulcrum Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $63M

Fulcrum Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    FULC return on invested capital is -8.07%
  • What Is Fulcrum Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -7.42%
  • What Is FULC Return On Equity?
    ROE is a measure of profitability and is -8.07%

Fulcrum Therapeutics Earnings Date & Stock Price

Fulcrum Therapeutics Competitors

Fulcrum Therapeutics Dividend Yield

Fulcrum Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 1.63%
Revenue: 8990.91% -100%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 5.29
Upside from Last Price: 62.14%

Major Shareholders

  • How many FULC shares are owned by institutional investors?
    109.8M FULC shares are owned by institutional investors
  • How many FULC shares are owned by insiders?
    1.1M FULC shares are owned by insiders